Early Toxicity Testing Market by Technique (In Vivo, In Vitro, and In Silico), by Toxicity Endpoint (Genotoxicity, Dermal Toxicity, Skin Toxicity, Ocular Toxicity, Phototoxicity, and Others), by End User (Pharmaceutical Industry, Cosmetic Industry, Chemic

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,975	306 Pages	Next Move Strategy Consulting	May, 2023	NMSC18104093

Best Price Guarantee
Price	from $3,975
Length	306 Pages
Publisher	Next Move Strategy Consulting
Published Date	May, 2023
SKU	NMSC18104093

Early Toxicity Testing Market by Technique (In Vivo, In Vitro, and In Silico), by Toxicity Endpoint (Genotoxicity, Dermal Toxicity, Skin Toxicity, Ocular Toxicity, Phototoxicity, and Others), by End User (Pharmaceutical Industry, Cosmetic Industry, Chemical Industry, Food Industry, and Others) – Global Opportunity Analysis and Industry Forecast, 2023-2030

The Early Toxicity Testing (ETT) Market size was valued at USD 8.92 billion in 2022, and is predicted to reach USD 14.39 billion by 2030, at a CAGR of 5.3% during the forecast period, 2023–2030.

The safety testing of new chemicals is now subjected to stricter global regulations. There is a greater focus on animal welfare and the adoption of alternative testing methods. This has led to the development of new and innovative toxicity testing methods that are faster, more accurate, and more cost-effective than before.

However, developing and validating new toxicity testing methods can be costly and time-consuming, which can limit their adoption and use by companies and organizations. This factor is expected to restrain the growth of the market.

On the contrary, there is a growing demand for alternative toxicity testing methods that can reduce animal testing and provide faster and more accurate results. This presents an opportunity to develop new and innovative testing methods, such as in vitro assays, organ-on-chip technology, and computational modeling. These factors are expected to create ample growth opportunities for the market in the coming years.

Segment Overview
The global early toxicity testing industry is segmented on the basis of technique, toxicity endpoint, end users, and region.
By technique, the market is classified into in vivo, in vitro, and in silico.
By toxicity endpoint, the market is divided into genotoxicity, dermal toxicity, skin toxicity, ocular toxicity, phototoxicity, and others.
By end user, the market is divided into pharmaceutical industry, cosmetic industry, chemical industry, food industry, and others.
By region, the market is classified into North America, Europe, Asia-Pacific, and RoW.

Regional Analysis
Asia-Pacific is projected to dominate the early toxicity testing industry
The Asia-Pacific region has been witnessing a significant growth in the early toxicity testing industry, due to the increasing demand for new drugs, the rising investments in research and development activities, and the growing awareness of animal welfare.

Moreover, the Asia-Pacific region has been attracting significant investments from leading pharmaceutical and biotechnology companies, which are expanding their research and development activities in the region. The increasing number of contract research organizations (CROs) in the region is another factor contributing to the growth of the early toxicity testing industry.

Key Market Players
Leading players in the global early toxicity testing market include companies such as:
• Eurofins Scientific
• Wuxi Apptec
• Danaher Corporation
• Thermo Fisher Scientific, Inc.
• Perkinelmer, Inc.
• Charles River Laboratories
• Bio-Rad Laboratories, Inc.
• Labcorp Drug Development
• Agilent Technologies, Inc.
• Evotec AG

Recent Developments
April 2023
Agilent Technologies Inc. acquired Avida Biomed, a contract research organization specializing in vitro and in vivo toxicity testing, including ADME/DMPK studies. This acquisition will expand Agilent's capability in preclinical drug development, including early toxicity testing, and complement its existing portfolio of pharmaceutical research and development solutions.

February 2023
Evotec received a USD 159 million loan from the European Investment Bank (EIB) to support the development of innovative drug candidates. This funding will support the Company’s R&D activities, equity investments, and the building of the new J.POD biologics manufacturing facility on Evotec’s Campus Curie in Toulouse, France.

October 2022
Bio-Rad introduced anti-evolocumab antibodies for preclinical and clinical drug development. These new antibodies facilitate the study of Evolocumab, a monoclonal antibody used to lower cholesterol levels. They will also aid in developing novel therapies for cardiovascular diseases. The antibodies are designed to be highly specific and sensitive, making them valuable tools for researchers in drug discovery and development.

July 2022
Inotiv, Inc. acquired genetic toxicology assets from Merck's Bioreliance portfolio to expand its genetic toxicology testing capabilities. The acquisition includes two laboratories, first in Edinburgh, Scotland and another in Carlsbad, California. These laboratories specialize in genetic toxicology testing. This acquisition will enable Inotiv to provide additional genetic toxicology testing services to its clients. This will allow them to identify potential safety issues in their compounds and accelerate the development of safe and effective drugs.

July 2022
WuXi AppTec announced the setup of a global innovation center in Singapore, focusing on developing cutting-edge technologies and solutions, including AI and big data. Furthermroe it focuses on accelerating drug discovery and development. The center will also house the company's existing drug screening & profiling platform and preclinical development services.

KEY BENEFITS
• The early toxicity testing market report provides a quantitative analysis of the current market and estimations from 2023 to 2030. This analysis assists in identifying prevailing market opportunities.
• The study comprises a deep-dive analysis of the early toxicity testing market trends, including current and future trends to depict prevalent investment pockets in the market.
• The information related to key drivers, restraints, and opportunities and their impact on the early toxicity testing market is provided in the report.
• The competitive analysis of the market players along with their market share in the early toxicity testing market is provided in the report.
• The SWOT analysis and Porter’s Five Forces model have been elaborated in the study.
• The value chain analysis in the market study provides a clear picture of the role of stakeholders.

1. Introduction: 1.1. Report Description; 1.2. Who Should Read This Report; 1.3. Key Market Segments; 1.4. Research Methodology; 1.4.1 Secondary Research; 1.4.2 Data Analysis Framework; 1.4.3 Market Size Estimation; 1.4.4 Forecasting; 1.4.5 Primary Research And Data Validation
2. Early Toxicity Testing Market – Executive Summary: 2.1. Market Snapshot, 2022 - 2030, Million Usd
3. Market Overview: 3.1. Market Definition And Scope; 3.2. Market Dynamics; 3.2.1 Drivers; 3.2.1.1. Growth In Research And Development Activities; 3.2.1.2. Growth In Prevalence Of Chronic Diseases And Need For New Treatments; 3.2.2 Restraints; 3.2.2.1. Stringent Regulations; 3.2.3 Opportunities; 3.2.3.1. Development Of New Technologies
4. Market Share Analysis: 4.1. Market Share Analysis Of Top Early Toxicity Testing Providers, 2022
5. Global Early Toxicity Testing Market, By Technique: 5.1. Overview; 5.2. In Vivo; 5.2.1 In Vivo Market, By Region; 5.3. In Vitro; 5.3.1 Global In Vitro Market, By Technique; 5.3.1.1. Cell Culture Market, By Region; 5.3.1.2. Pcr Market, By Region; 5.3.1.3. Elisa Market, By Region; 5.3.1.4. Western Blotting Market, By Region; 5.3.1.5. Protein Binding Assays Market, By Region; 5.3.2 In Vitro Market, By Region; 5.4. In Silico; 5.4.1 In Silico Market, By Region
6. Global Early Toxicity Testing Market, By Toxicity Endpoints: 6.1. Overview; 6.2. Genotoxicity; 6.2.1 Genotoxicity Market, By Region; 6.3. Dermal Toxicity; 6.3.1 Dermal Toxicity Market, By Region; 6.4. Skin Toxicity; 6.4.1 Skin Toxicity Market, By Region; 6.5. Ocular Toxicity; 6.5.1 Ocular Toxicity Market, By Region; 6.6. Phototoxicity; 6.6.1 Phototoxicity Market, By Region; 6.7. Others; 6.7.1 Others Market, By Region
7. Global Early Toxicity Testing Market, By End User: 7.1. Overview; 7.2. Pharmaceutical Industry; 7.2.1 Pharmaceutical Industry Market, By Region; 7.3. Cosmetic Industry; 7.3.1 Cosmetic Industry Market, By Region; 7.4. Chemical Industry; 7.4.1 Chemical Industry Market, By Region; 7.5. Food Industry; 7.5.1 Food Industry Market, By Region; 7.6. Others; 7.6.1 Others Market, By Region
8. Global Early Toxicity Testing Market, By Region: 8.1. Overview; 8.2. North America; 8.2.1 North America Early Toxicity Testing Market, By Technique; 8.2.1.1. North America In Vitro Market, By Technique; 8.2.2 North America Early Toxicity Testing Market, By Toxicity Endpoints; 8.2.3 North America Early Toxicity Testing Market, By End User; 8.2.4 North America Early Toxicity Testing Market, By Country; 8.2.4.1. U.S.; 8.2.4.1.1. U.S. Early Toxicity Testing Market, By Technique; 8.2.4.1.1.1. U.S. In Vitro Market, By Technique; 8.2.4.1.2. U.S. Early Toxicity Testing Market, By Toxicity Endpoints; 8.2.4.1.3. U.S. Early Toxicity Testing Market, By End User; 8.2.4.2. Canada; 8.2.4.2.1. Canada Early Toxicity Testing Market, By Technique; 8.2.4.2.1.1. Canada In Vitro Market, By Technique; 8.2.4.2.2. Canada Early Toxicity Testing Market, By Toxicity Endpoints; 8.2.4.2.3. Canada Early Toxicity Testing Market, By End User; 8.2.4.3. Mexico; 8.2.4.3.1. Mexico Early Toxicity Testing Market, By Technique; 8.2.4.3.1.1. Mexico In Vitro Market, By Technique; 8.2.4.3.2. Mexico Early Toxicity Testing Market, By Toxicity Endpoints; 8.2.4.3.3. Mexico Early Toxicity Testing Market, By End User; 8.3. Europe; 8.3.1 Europe Early Toxicity Testing Market, By Technique; 8.3.1.1. Europe In Vitro Market, By Technique; 8.3.2 Europe Early Toxicity Testing Market, By Toxicity Endpoints; 8.3.3 Europe Early Toxicity Testing Market, By End User; 8.3.4 Europe Early Toxicity Testing Market, By Country; 8.3.4.1. Uk; 8.3.4.1.1. Uk Early Toxicity Testing Market, By Technique; 8.3.4.1.1.1. Uk In Vitro Market, By Technique; 8.3.4.1.2. Uk Early Toxicity Testing Market, By Toxicity Endpoints; 8.3.4.1.3. Uk Early Toxicity Testing Market, By End User; 8.3.4.2. Germany; 8.3.4.2.1. Germany Early Toxicity Testing Market, By Technique; 8.3.4.2.1.1. Germany In Vitro Market, By Technique; 8.3.4.2.2. Germany Early Toxicity Testing Market, By Toxicity Endpoints; 8.3.4.2.3. Germany Early Toxicity Testing Market, By End User; 8.3.4.3. France; 8.3.4.3.1. France Early Toxicity Testing Market, By Technique; 8.3.4.3.1.1. France In Vitro Market, By Technique; 8.3.4.3.2. France Early Toxicity Testing Market, By Toxicity Endpoints; 8.3.4.3.3. France Early Toxicity Testing Market, By End User; 8.3.4.4. Italy; 8.3.4.4.1. Italy Early Toxicity Testing Market, By Technique; 8.3.4.4.1.1. Italy In Vitro Market, By Technique; 8.3.4.4.2. Italy Early Toxicity Testing Market, By Toxicity Endpoints; 8.3.4.4.3. Italy Early Toxicity Testing Market, By End User; 8.3.4.5. Spain; 8.3.4.5.1. Spain Early Toxicity Testing Market, By Technique; 8.3.4.5.1.1. Spain In Vitro Market, By Technique; 8.3.4.5.2. Spain Early Toxicity Testing Market, By Toxicity Endpoints; 8.3.4.5.3. Spain Early Toxicity Testing Market, By End User; 8.3.4.6. Netherlands; 8.3.4.6.1. Netherlands Early Toxicity Testing Market, By Technique; 8.3.4.6.1.1. Netherlands In Vitro Market, By Technique; 8.3.4.6.2. Netherlands Early Toxicity Testing Market, By Toxicity Endpoints; 8.3.4.6.3. Netherlands Early Toxicity Testing Market, By End User; 8.3.4.7. Denmark; 8.3.4.7.1. Denmark Early Toxicity Testing Market, By Technique; 8.3.4.7.1.1. Denmark In Vitro Market, By Technique; 8.3.4.7.2. Denmark Early Toxicity Testing Market, By Toxicity Endpoints; 8.3.4.7.3. Denmark Early Toxicity Testing Market, By End User; 8.3.4.8. Finland; 8.3.4.8.1. Finland Early Toxicity Testing Market, By Technique; 8.3.4.8.1.1. Finland In Vitro Market, By Technique; 8.3.4.8.2. Finland Early Toxicity Testing Market, By Toxicity Endpoints; 8.3.4.8.3. Finland Early Toxicity Testing Market, By End User; 8.3.4.9. Norway; 8.3.4.9.1. Norway Early Toxicity Testing Market, By Technique; 8.3.4.9.1.1. Norway In Vitro Market, By Technique; 8.3.4.9.2. Norway Early Toxicity Testing Market, By Toxicity Endpoints; 8.3.4.9.3. Norway Early Toxicity Testing Market, By End User; 8.3.4.10. Sweden; 8.3.4.10.1. Sweden Early Toxicity Testing Market, By Technique; 8.3.4.10.1.1. Sweden In Vitro Market, By Technique; 8.3.4.10.2. Sweden Early Toxicity Testing Market, By Toxicity Endpoints; 8.3.4.10.3. Sweden Early Toxicity Testing Market, By End User; 8.3.4.11. Russia; 8.3.4.11.1. Russia Early Toxicity Testing Market, By Technique; 8.3.4.11.1.1. Russia In Vitro Market, By Technique; 8.3.4.11.2. Russia Early Toxicity Testing Market, By Toxicity Endpoints; 8.3.4.11.3. Russia Early Toxicity Testing Market, By End User; 8.3.4.12. Rest Of Europe; 8.3.4.12.1. Rest Of Europe Early Toxicity Testing Market, By Technique; 8.3.4.12.1.1. Rest Of Europe In Vitro Market, By Technique; 8.3.4.12.2. Rest Of Europe Early Toxicity Testing Market, By Toxicity Endpoints; 8.3.4.12.3. Rest Of Europe Early Toxicity Testing Market, By End User; 8.4. Asia-pacific; 8.4.1 Asia-pacific Early Toxicity Testing Market, By Technique; 8.4.1.1. Asia-pacific In Vitro Market, By Technique; 8.4.2 Asia-pacific Early Toxicity Testing Market, By Toxicity Endpoints; 8.4.3 Asia-pacific Early Toxicity Testing Market, By End User; 8.4.4 Asia-pacific Early Toxicity Testing Market, By Country; 8.4.4.1. Australia; 8.4.4.1.1. Australia Early Toxicity Testing Market, By Technique; 8.4.4.1.1.1. Australia In Vitro Market, By Technique; 8.4.4.1.2. Australia Early Toxicity Testing Market, By Toxicity Endpoints; 8.4.4.1.3. Australia Early Toxicity Testing Market, By End User; 8.4.4.2. China; 8.4.4.2.1. China Early Toxicity Testing Market, By Technique; 8.4.4.2.1.1. China In Vitro Market, By Technique; 8.4.4.2.2. China Early Toxicity Testing Market, By Toxicity Endpoints; 8.4.4.2.3. China Early Toxicity Testing Market, By End User; 8.4.4.3. India; 8.4.4.3.1. India Early Toxicity Testing Market, By Technique; 8.4.4.3.1.1. India In Vitro Market, By Technique; 8.4.4.3.2. India Early Toxicity Testing Market, By Toxicity Endpoints; 8.4.4.3.3. India Early Toxicity Testing Market, By End User; 8.4.4.4. Indonesia; 8.4.4.4.1. Indonesia Early Toxicity Testing Market, By Technique; 8.4.4.4.1.1. Indonesia In Vitro Market, By Technique; 8.4.4.4.2. Indonesia Early Toxicity Testing Market, By Toxicity Endpoints; 8.4.4.4.3. Indonesia Early Toxicity Testing Market, By End User; 8.4.4.5. Japan; 8.4.4.5.1. Japan Early Toxicity Testing Market, By Technique; 8.4.4.5.1.1. Japan In Vitro Market, By Technique; 8.4.4.5.2. Japan Early Toxicity Testing Market, By Toxicity Endpoints; 8.4.4.5.3. Japan Early Toxicity Testing Market, By End User; 8.4.4.6. Singapore; 8.4.4.6.1. Singapore Early Toxicity Testing Market, By Technique; 8.4.4.6.1.1. Singapore In Vitro Market, By Technique; 8.4.4.6.2. Singapore Early Toxicity Testing Market, By Toxicity Endpoints; 8.4.4.6.3. Singapore Early Toxicity Testing Market, By End User; 8.4.4.7. South Korea; 8.4.4.7.1. South Korea Early Toxicity Testing Market, By Technique; 8.4.4.7.1.1. South Korea In Vitro Market, By Technique; 8.4.4.7.2. South Korea Early Toxicity Testing Market, By Toxicity Endpoints; 8.4.4.7.3. South Korea Early Toxicity Testing Market, By End User; 8.4.4.8. Taiwan; 8.4.4.8.1. Taiwan Early Toxicity Testing Market, By Technique; 8.4.4.8.1.1. Taiwan In Vitro Market, By Technique; 8.4.4.8.2. Taiwan Early Toxicity Testing Market, By Toxicity Endpoints; 8.4.4.8.3. Taiwan Early Toxicity Testing Market, By End User; 8.4.4.9. Thailand; 8.4.4.9.1. Thailand Early Toxicity Testing Market, By Technique; 8.4.4.9.1.1. Thailand In Vitro Market, By Technique; 8.4.4.9.2. Thailand Early Toxicity Testing Market, By Toxicity Endpoints; 8.4.4.9.3. Thailand Early Toxicity Testing Market, By End User; 8.4.4.10. Rest Of Asia-pacific; 8.4.4.10.1. Rest Of Asia-pacific Early Toxicity Testing Market, By Technique; 8.4.4.10.1.1. Rest Of Asia-pacific In Vitro Market, By Technique; 8.4.4.10.2. Rest Of Asia-pacific Early Toxicity Testing Market, By Toxicity Endpoints; 8.4.4.10.3. Rest Of Asia-pacific Early Toxicity Testing Market, By End User; 8.5. Rest Of World; 8.5.1 Rest Of World Early Toxicity Testing Market, By Technique; 8.5.1.1. Rest Of World In Vitro Market, By Technique; 8.5.2 Rest Of World Early Toxicity Testing Market, By Toxicity Endpoints; 8.5.3 Rest Of World Early Toxicity Testing Market, By End User; 8.5.4 Rest Of World Early Toxicity Testing Market, By Country; 8.5.4.1. Latin America; 8.5.4.1.1. Latin America Early Toxicity Testing Market, By Technique; 8.5.4.1.1.1. Latin America In Vitro Market, By Technique; 8.5.4.1.2. Latin America Early Toxicity Testing Market, By Toxicity Endpoints; 8.5.4.1.3. Latin America Early Toxicity Testing Market, By End User; 8.5.4.2. Middle East; 8.5.4.2.1. Middle East Early Toxicity Testing Market, By Technique; 8.5.4.2.1.1. Middle East In Vitro Market, By Technique; 8.5.4.2.2. Middle East Early Toxicity Testing Market, By Toxicity Endpoints; 8.5.4.2.3. Middle East Early Toxicity Testing Market, By End User; 8.5.4.3. Africa; 8.5.4.3.1. Africa Early Toxicity Testing Market, By Technique; 8.5.4.3.1.1. Africa In Vitro Market, By Technique; 8.5.4.3.2. Africa Early Toxicity Testing Market, By Toxicity Endpoints; 8.5.4.3.3. Africa Early Toxicity Testing Market, By End User
9. Company Profiles: 9.1. Inotiv Inc.; 9.1.1 Company Overview; 9.1.2 Company Snapshot; 9.1.3 Operating Business Segments; 9.1.4 Product Portfolio; 9.1.5 Business Performance; 9.1.6 Sales By Business Segment; 9.1.7 Sales By Geographic Segment; 9.1.8 Key Strategic Moves & Developments; 9.1.9 Primary Market Competitors; 9.2. Bio-rad Laboratories Inc; 9.2.1 Company Overview; 9.2.2 Company Snapshot; 9.2.3 Operating Business Segments; 9.2.4 Product Portfolio; 9.2.5 Business Performance; 9.2.6 Sales By Business Segment; 9.2.7 Sales By Geographic Segment; 9.2.8 Key Strategic Moves & Developments; 9.2.9 Primary Market Competitors; 9.3. Evotec A.G.; 9.3.1 Company Overview; 9.3.2 Company Snapshot; 9.3.3 Operating Business Segments; 9.3.4 Product Portfolio; 9.3.5 Business Performance; 9.3.6 Sales By Business Segment; 9.3.7 Sales By Geographic Segment; 9.3.8 Key Strategic Moves & Developments; 9.3.9 Primary Market Competitors; 9.4. Agilent Technologies Inc; 9.4.1 Company Overview; 9.4.2 Company Snapshot; 9.4.3 Operating Business Segment; 9.4.4 Product Portfolio; 9.4.5 Business Performance; 9.4.6 Sales By Business Segment; 9.4.7 Sales By Geographic Segment; 9.4.8 Key Strategic Moves & Developments; 9.4.9 Primary Market Competitors; 9.5. Wuxi Apptec; 9.5.1 Company Overview; 9.5.2 Company Snapshot; 9.5.3 Operating Business Segments; 9.5.4 Product Portfolio; 9.5.5 Business Performance; 9.5.6 Sales By Business Segment; 9.5.7 Sales By Geographic Segment; 9.5.8 Key Strategic Moves & Developments; 9.5.9 Primary Market Competitors; 9.7. Bruker; 9.7.1 Company Overview; 9.7.2 Company Snapshot; 9.7.3 Operating Business Segment; 9.7.4 Product Portfolio; 9.7.5 Business Performance; 9.7.6 Sales By Business Segment; 9.7.7 Sales By Geographic Segment; 9.7.8 Key Strategic Moves & Developments; 9.7.9 Primary Market Competitors; 9.8. Perkinelmer Inc.; 9.8.1 Company Overview; 9.8.2 Company Snapshot; 9.8.3 Operating Business Segment; 9.8.4 Product Portfolio; 9.8.5 Business Performance; 9.8.6 Sales By Business Segment; 9.8.7 Sales By Geographic Segment; 9.8.8 Key Strategic Moves & Developments; 9.8.9 Primary Market Competitors; 9.9. Enzo Biochem Inc.; 9.9.1 Company Overview; 9.9.2 Company Snapshot; 9.9.3 Operating Business Segment; 9.9.4 Product Portfolio; 9.9.5 Business Performance; 9.9.6 Sales By Business Segment; 9.9.7 Sales By Geographic Segment; 9.9.8 Key Strategic Moves & Developments; 9.9.9 Primary Market Competitors; 9.10. Danaher Corporation; 9.10.1 Company Overview; 9.10.2 Company Snapshot; 9.10.3 Operating Business Segments; 9.10.4 Product Portfolio; 9.10.5 Business Performance; 9.10.6 Sales By Business Segment; 9.10.7 Key Strategic Moves & Developments; 9.10.8 Primary Market Competitors; 9.11. Eurofins Scientific Se; 9.11.1 Company Overview; 9.11.2 Company Snapshot; 9.11.3 Product Portfolio; 9.11.4 Business Performance; 9.11.5 Sales By Geographic Segment; 9.11.6 Key Strategic Moves & Developments; 9.11.7 Primary Market Competitors; 9.12. Charles River Laboratories International, Inc.; 9.12.1 Company Overview; 9.12.2 Company Snapshot; 9.12.3 Operating Business Segments; 9.12.4 Product Portfolio; 9.12.5 Business Performance; 9.12.6 Sales By Business Segment; 9.12.7 Sales By Geographic Segment; 9.12.8 Key Strategic Moves & Developments; 9.12.9 Primary Market Competitors; 9.13. Labcorp Drug Development.; 9.13.1 Company Overview; 9.13.2 Company Snapshot; 9.13.3 Operating Business Segments; 9.13.4 Product Portfolio; 9.13.5 Business Performance; 9.13.6 Sales By Business Segment; 9.13.7 Sales By Geographic Segment; 9.13.8 Key Strategic Moves & Developments; 9.13.9 Primary Market Competitors; 9.14. Promega Corporation; 9.14.1 Company Overview; 9.14.2 Company Snapshot; 9.14.3 Product Portfolio; 9.14.4 Key Strategic Moves & Developments; 9.14.5 Promega Corporation: Key Strategic Moves & Developments; 9.14.6 Primary Market Competitors; 9.15. Insphero Ag; 9.15.1 Company Overview; 9.15.2 Company Snapshot; 9.15.3 Product Portfolio; 9.15.4 Key Strategic Moves & Developments; 9.15.5 Insphero Ag: Key Strategic Moves & Developments; 9.15.6 Primary Market Competitors